Investigational Drug Information for Merestinib
✉ Email this page to a colleague
What is the development status for investigational drug Merestinib?
Merestinib is an investigational drug.
There have been 8 clinical trials for Merestinib.
The most recent clinical trial was a Phase 1 trial, which was initiated on May 19th 2016.
The most common disease conditions in clinical trials are Neoplasms, Neoplasm Metastasis, and Leukemia. The leading clinical trial sponsors are Eli Lilly and Company, Dana-Farber Cancer Institute, and Jacqueline Garcia, MD.
There are nine US patents protecting this investigational drug and two hundred and twenty international patents.
Summary for Merestinib
| US Patents | 9 |
| International Patents | 220 |
| US Patent Applications | 97 |
| WIPO Patent Applications | 104 |
| Japanese Patent Applications | 26 |
| Clinical Trial Progress | Phase 1 (2016-05-19) |
| Vendors | 48 |
Recent Clinical Trials for Merestinib
| Title | Sponsor | Phase |
|---|---|---|
| Merestinib on Bone Metastases in Subjects With Breast Cancer | Eli Lilly and Company | Phase 1 |
| Merestinib on Bone Metastases in Subjects With Breast Cancer | University of Utah | Phase 1 |
| Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia | Eli Lilly and Company | Phase 1 |
Clinical Trial Summary for Merestinib
Top disease conditions for Merestinib
Top clinical trial sponsors for Merestinib
US Patents for Merestinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Merestinib | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Merestinib | ⤷ Sign Up | Methods of treating a neuroendocrine tumor | SCRIPPS HEALTH (San Diego, CA) | ⤷ Sign Up |
| Merestinib | ⤷ Sign Up | Tank-binding kinase inhibitor compounds | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign Up |
| Merestinib | ⤷ Sign Up | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (West Conshohocken, PA) | ⤷ Sign Up |
| Merestinib | ⤷ Sign Up | Combination therapy with an anti-axl antibody-drug conjugate | ADC THERAPEUTICS SA (Epalinges, CH) MEDIMMUNE LIMTIED (Cambridge, GB) | ⤷ Sign Up |
| Merestinib | ⤷ Sign Up | Macrocylic compounds as ROS1 kinase inhibitors | Array BioPharma Inc. (Boulder, CO) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Merestinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Merestinib | Australia | AU2017261372 | 2036-05-05 | ⤷ Sign Up |
| Merestinib | Canada | CA3023278 | 2036-05-05 | ⤷ Sign Up |
| Merestinib | China | CN107847398 | 2036-05-05 | ⤷ Sign Up |
| Merestinib | European Patent Office | EP3452003 | 2036-05-05 | ⤷ Sign Up |
| Merestinib | European Patent Office | EP3981392 | 2036-05-05 | ⤷ Sign Up |
| Merestinib | Hong Kong | HK1249728 | 2036-05-05 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
